{"id":"W4414443225","doi":"10.1080/14728214.2025.2565189","title":"Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Clinical trial; Myelin oligodendrocyte glycoprotein; Multiple sclerosis; Immunotherapy; Clinical neurology; Targeted therapy; Disease; MEDLINE","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001356742,0.000892199,0.003077403,0.0003614301,0.0006424608,0.00007651209,0.0005993348,0.0005519855,0.0001050948],"category_scores_gemma":[0.003024483,0.0005183549,0.002451247,0.000627432,0.0001644531,0.0000573634,0.0002860321,0.0009596763,0.00006665951],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003743155,"about_ca_system_score_gemma":0.001163178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003175721,"about_ca_topic_score_gemma":0.000002974082,"domain_scores_codex":[0.9942701,0.000993643,0.001588748,0.001203827,0.001106112,0.0008375178],"domain_scores_gemma":[0.9952109,0.002302916,0.0006258945,0.001222843,0.0002407251,0.0003966527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008369821,0.0009302186,0.0000129689,0.003164274,0.002339109,0.000008242899,0.0001838208,4.130156e-7,2.841094e-7,0.00005851424,0.07365125,0.9112811],"study_design_scores_gemma":[0.02977147,0.0007452343,0.0000854817,0.0247601,0.0004450114,9.399048e-7,0.000150634,0.00007507533,9.993136e-7,0.000004085925,0.9435549,0.0004060654],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001894401,0.979951,0.00002449902,0.003484577,0.005519471,0.009840284,0.000433466,0.0001985305,0.0005292722],"genre_scores_gemma":[0.00002210279,0.9812874,0.0001271146,0.0003821566,0.008420593,0.004233332,0.003097315,0.0001223198,0.002307687],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.910875,"threshold_uncertainty_score":0.9997268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1193818646769692,"score_gpt":0.4944612600731487,"score_spread":0.3750793953961795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}